Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.61 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.61 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.61 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.61 |
| ▸ | DGKA | P23743 | 1/20 | 0.60 |
| ▸ | FAAH | O00519 | 3/20 | 0.58 |
| ▸ | CNR2 | P34972 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.52 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4345443 | 1.00 | PRKCA (0.61) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL4343073 | 1.00 | PRKCA (0.61) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL4337617 | 1.00 | PRKCA (0.61) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL8635209 | 0.87 | PRKCA (0.63) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL5680978 | 0.87 | PRKCA (0.63) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL23781814 | 0.84 | PRKCA (0.60) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL11474473 | 0.84 | PRKCA (0.60) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL28606688 | 0.84 | PRKCA (0.60) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL714739 | 0.83 | PRKCA (0.59) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL8344879 | 0.83 | PRKCA (0.59) | PRKCAPRKCEPRKCQPRKCDDGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829527-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1829528-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1815846-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| EP-1815847-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| EP-1551370-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2005-07-13 | — | — | EP | claimed |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2004-06-03 | — | — | US | claimed |
| WO-2004032900-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2004-04-22 | — | — | WO | claimed |
| US-20120177698-A1 | AGGREGATES WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | CEVC GREGOR (DE) | 2012-07-12 | — | — | US | disclosed |
| CN-101862295-A | Aggregate having enhanced deformability and including at least three amphipatic substances | IDEA AG | 2010-10-20 | — | — | CN | disclosed |
| CN-1703199-B | Aggregate with enhanced deformability comprising at least three amphiphiles for improved transport through a semi-permeable barrier and use of non-invasive drugs in vivo, in particular through the skin | IDEA AG | 2010-04-28 | — | — | CN | disclosed |
| US-20090155235-A1 | AGGREGATES WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2009-06-18 | — | — | US | disclosed |
| US-20090060989-A1 | NSAID FORMULATIONS, BASED ON HIGHLY ADAPTABLE AGGREGATES, FOR IMPROVED TRANSPORT THROUGH BARRIERS AND TOPICAL DRUG DELIVERY | IDEA AG (DE) | 2009-03-05 | — | — | US | disclosed |
| US-20090060990-A1 | NSAID FORMULATIONS, BASED ON HIGHLY ADAPTABLE AGGREGATES, FOR IMPROVED TRANSPORT THROUGH BARRIERS AND TOPICAL DRUG DELIVERY | IDEA AG (DE) | 2009-03-05 | — | — | US | disclosed |
| WO-2004032900-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2004-04-22 | — | — | WO | disclosed |
| US-20040071767-A1 | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery | IDEA AG (DE) | 2004-04-15 | — | — | US | disclosed |
| EP-0088046-B1 | LIPIDS IN THE AQUEOUS PHASE | CIBA-GEIGY AG (CH) | 1987-12-09 | — | — | EP | disclosed |
| US-4619794-A | Spontaneous preparation of small unilamellar liposomes | CIBA-GEIGY CORPORATION (US) | 1986-10-28 | — | — | US | disclosed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | disclosed |
| EP-0102324-A2 | Lipids and surfactants in an aqueous medium | CIBA-GEIGY AG (CH) | 1984-03-07 | — | — | EP | disclosed |
| EP-0088046-A2 | Lipids in the aqueous phase | CIBA-GEIGY AG (CH) | 1983-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040071767-A1 | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery | SLC43A1, TRPV2, TRPA1 | PRKCA 3393/4885PRKCE 3766/4885PRKCQ 3672/4885 |
| US-20090060989-A1 | NSAID FORMULATIONS, BASED ON HIGHLY ADAPTABLE AGGREGATES, FOR IMPROVED TRANSPORT THROUGH BARRIERS AND TOPICAL DRUG DELIVERY | SLC43A1, TRPV2, TRPA1 | PRKCA 3393/4885PRKCE 3766/4885PRKCQ 3672/4885 |
| US-20120177698-A1 | AGGREGATES WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | CUTA, ABCG2, ABCB11 | PRKCA 2037/4885PRKCE 2192/4885PRKCQ 1167/4885 |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | PRKCA 1831/4885PRKCE 2118/4885PRKCQ 1398/4885 |
| US-20090060990-A1 | NSAID FORMULATIONS, BASED ON HIGHLY ADAPTABLE AGGREGATES, FOR IMPROVED TRANSPORT THROUGH BARRIERS AND TOPICAL DRUG DELIVERY | SLC43A1, TRPV2, TRPA1 | PRKCA 3393/4885PRKCE 3766/4885PRKCQ 3672/4885 |
| US-20090155235-A1 | AGGREGATES WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | CUTA, ABCG2, PIGS | PRKCA 1696/4885PRKCE 1998/4885PRKCQ 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.